clinical trial · NCT07087795
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes
Novo Nordisk A/S·phase1·active not recruiting·n = 96
Diabetes Mellitus, Type 1NNC0194-0499PlaceboSemaglutide
brief summary
This study is testing the effect of a new study medicine NNC0194-0499 in type 1 diabetes. The purpose of the study is to compare the effect of NNC0194-0499 on the blood sugar levels of participants with type 1 diabetes when taken in combination with semaglutide or placebo. All participants will receive standard of care insulin treatment. The study will last for about 36 weeks.
started
Jul 1, 2025
primary completion
Sep 12, 2026
completion
Sep 25, 2026
last updated
Aug 13, 2026
official title
A Study to Investigate Efficacy and Safety of NNC0194-0499 Versus Placebo, Both Administered Alone or in Combination With Semaglutide in People With Type 1 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol